Innovations in pharmacotherapy for stress urinary incontinence.
The purpose of this review article is to highlight new pharmacotherapies on the horizon for the treatment of stress urinary incontinence (SUI). Although behavioral and surgical therapies are currently the mainstay of treating SUI, we believe that medications will take center stage and possibly become first-line therapy. Currently, there are no FDA medications indicated for SUI. However, results are becoming available about an oral medication, duloxetine, which appears to be clinically safe and efficacious for the treatment of SUI. In addition to discussing medications currently under development, we will also discuss exciting pharmacological targets that could be suitable to treat SUI.
Cannon
Tracy W
TW
Department of Urology, University of Pittsburgh, Lillian S. Kaufmann Building, 3471 Fifth Avenue, Suite 801, PA 15213, Pittsburgh, USA.
Yoshimura
Naoki
N
Chancellor
Michael B
MB
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D014550:Urinary Incontinence, Stress / Q000188:drug therapy* / Q000503:physiopathology
D018759:Adrenergic Uptake Inhibitors; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes